Cassava Sciences Inc • SAVA

SAVA current price
$2.55-88.67%

Capital at risk.

1W
+4.08%
1M
-37.35%
3M
-92.00%
6M
-86.54%
1Y
-88.67%
MAX
-82.23%
About Cassava Sciences Inc
Ticker
info
SAVA
Trading on
info
NASDAQ
ISIN
info
US14817C1071
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Richard Jon Barry
Headquarters
info
6801 N. Capital of Texas Highway, Austin, TX, United States, 78731
Employees
info
29
Website
info
cassavasciences.com
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Metrics
BasicAdvanced
Market cap
info
$113M
P/E ratio
info
-
EPS
info
-$1.38
Dividend Yield
info
0.00%
Beta
info
-0.58
Forward P/E ratio
info
151.52
EBIDTA
info
$-143M
Ex dividend date
info
2012-12-13
Price & volume
Market cap
info
$113M
Average daily volume
info
7.7M
90-day return
info
-92.00%
30-day return
info
-37.35%
7-day return
info
4.08%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
151.52
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
0.7
Earnings
EPS
info
-$1.38
EPS estimate (current quarter)
info
-$0.88
EPS estimate (next quarter)
info
-$0.99
EBITDA
info
$-143M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
-0.58
52-week High
info
$42.20
52-week Low
info
$2.23
50-day moving average
info
$17.52
200-day moving average
info
$21.01
Short ratio
info
1.95
Short %
info
38.06%
Management effectiveness
ROE (TTM)
info
10.98%
ROA (TTM)
info
45.60%
Profit margin
info
0.00%
Gross profit margin
info
$-68M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
48.1M
Float
info
42.9M
Insiders %
info
12.65%
Institutions %
info
29.93%
Analyst Insights & forecasts
info

0% Buy

100% Hold

0% Sell

Based on information from 2 analysts.

Average price target

info
$116.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.50
-$0.52
3.85%
Q4 • 23Beat
$0.58
-$0.46
226.09%
Q1 • 24Beat
$0.13
-$0.40
132.50%
Q2 • 24Beat
-$0.58
-$0.88
34.09%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$6.2M
∞%
Q2 • 24
$0M
$-27.9M
∞%
Q3 • 24
NaN%
553.99%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$244M
$54.6M
22.41%
Q2 • 24
$224M
$57.1M
25.53%
Q3 • 24
8.14%
4.62%
13.88%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-18.2M
$-0M
$101M
$-18.3M
Q2 • 24
$-18.3M
$-0M
$0M
$-18.3M
Q3 • 24
0.30%
41.38%
100.00%
0.24%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Neutral

+1.5

-0.01

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Cassava Sciences Inc share?
Collapse

Cassava Sciences Inc shares are currently traded for $2.55 per share.

How many shares does Cassava Sciences Inc have?
Collapse

Cassava Sciences Inc currently has 48.1M shares.

Does Cassava Sciences Inc pay dividends?
Collapse

No, Cassava Sciences Inc doesn't pay dividends.

What is Cassava Sciences Inc 52 week high?
Collapse

Cassava Sciences Inc 52 week high is $42.20.

What is Cassava Sciences Inc 52 week low?
Collapse

Cassava Sciences Inc 52 week low is $2.23.

What is the 200-day moving average of Cassava Sciences Inc?
Collapse

Cassava Sciences Inc 200-day moving average is $21.01.

Who is Cassava Sciences Inc CEO?
Collapse

The CEO of Cassava Sciences Inc is Richard Jon Barry.

How many employees Cassava Sciences Inc has?
Collapse

Cassava Sciences Inc has 29 employees.

What is the market cap of Cassava Sciences Inc?
Collapse

The market cap of Cassava Sciences Inc is $113M.

What is the P/E of Cassava Sciences Inc?
Collapse

The current P/E of Cassava Sciences Inc is null.

What is the EPS of Cassava Sciences Inc?
Collapse

The EPS of Cassava Sciences Inc is -$1.38.

What is the PEG Ratio of Cassava Sciences Inc?
Collapse

The PEG Ration of Cassava Sciences Inc is null.

What do analysts say about Cassava Sciences Inc?
Collapse

According to the analysts Cassava Sciences Inc is considered a hold.

Cassava Sciences Inc news
thumbs_up_down
•Neutral
Shareholders that lost money on Cassava Sciences, Inc. (SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118476&wire=1 or contact Joseph E. Levi, Esq.

Accesswire•25 Dec 2024, 01:30
thumbs_up_down
•Neutral
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.

GlobeNewsWire•25 Dec 2024, 01:02
thumbs_up_down
•Neutral
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join – Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118457&wire=1 or contact Joseph E. Levi, Esq.

Accesswire•24 Dec 2024, 21:15